Substance / Medication

Bromocriptine

Overview

Active Ingredient
bromocriptine
RxNorm CUI
1760

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

56 trials linked to this intervention

56
Total Trials
7
Recruiting
17
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and safety of bromocriptine in peripartum cardiomyopathy: A systematic review and meta-analysis.
Attachaipanich Tanawat, Attachaipanich Suthinee, Kaewboot Kotchakorn · Int J Cardiol · 2025
PMID: 40037477Meta-Analysis
Bromocriptine in peripartum cardiomyopathy: A meta-analysis with trial sequential analysis.
Adamu Umar G, Mojela Kabo, Karaye Kamilu M et al. · ESC Heart Fail · 2025
PMID: 41213878Meta-AnalysisFull text (PMC)
Comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine): Unveiling the strategy for lactation inhibition - A systematic review of clinical trials.
Shrateh Oadi N, Kumar Kanwal Ashok, Jawed Areesha et al. · J Gynecol Obstet Hum Reprod · 2024
PMID: 38554942Meta-Analysis
Efficacy and Safety of Bromocriptine-QR as an Adjunctive Therapy on Glycemic Control in Subjects with Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
Yanto Theo Audi, Budiputri Charista Lydia, Muljono Michelle Patricia et al. · J ASEAN Fed Endocr Soc · 2024
PMID: 38863918Meta-AnalysisFull text (PMC)
Effects of bromocriptine in peripartum cardiomyopathy: a systematic review and meta-analysis.
Trongtorsak Angkawipa, Kittipibul Veraprapas, Mahabir Sunita et al. · Heart Fail Rev · 2022
PMID: 34725781Meta-Analysis
Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review.
Huang Hai Yan, Lin Shao Jian, Zhao Wei Guo et al. · Metab Brain Dis · 2018
PMID: 29546691Meta-Analysis
Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Liang W, Gao L, Li N et al. · Horm Metab Res · 2015
PMID: 26332757Meta-Analysis
Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis.
dos Santos Nunes Vania, El Dib Regina, Boguszewski César Luiz et al. · Pituitary · 2011
PMID: 21221817Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Bromocriptine (substance)
SNOMED CT
387039007
UMLS CUI
C0006230
RxNorm CUI
1760

Clinical Data

This intervention maps to 13 entities in the Healos knowledge graph.

7
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
56
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.